Eiger Mountains

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International D-LIVR Study Enrolling - NDA and MAA filings for Progeria & Progeroid Laminopathies planned for Q4 2019 PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences in August
PALO ALTO, Calif. , Aug. 5, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in
View HTML
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
- Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the
View HTML
Toggle Summary Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
PALO ALTO, Calif. , June 10, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach , PhD, RPh as Vice President of Global Regulatory
View HTML
Toggle Summary Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
PALO ALTO, Calif. , June 5, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Global Hepatitis
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif. , May 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company's Chief Operating Officer
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International "D-LIVR" Study Underway - NDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019 - Strong Balance Sheet with Recent Financing Completed PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger to Present at ChinaBio® Partnering Forum 2019
PALO ALTO, Calif. , April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will participate and present a
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share.  All of the shares are being sold by Eiger.
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock.  All of the shares to be sold in the offering are to be sold by Eiger.
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
PALO ALTO, Calif. , April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev , JD to its Board of Directors.  Mr.
View HTML
Toggle Summary Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa - Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif. , March 26, 2019 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
- Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia - Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif. , March 25, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
PALO ALTO, Calif. , March 20, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Began 2019 with $100.4 million in cash, cash equivalents & short-term investments - Enrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019 - NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif. , March 14, 2019 /PRNewswire/ -- Eiger
View HTML
Toggle Summary Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
- 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif. , March 13, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a
View HTML
Toggle Summary Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
PALO ALTO, Calif. , March 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
PALO ALTO, Calif. , Feb. 27, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company's General Counsel,
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif. , Feb. 6, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today that the European
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
PALO ALTO, Calif. , Feb. 4, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results of the Phase 2 PREVENT study at ENDO 2019 in
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
PALO ALTO, Calif. , Jan. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray , MS, RAC to its Board of Directors.  Ms.
View HTML
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
- Survival Benefit in Children with Progeria Published in JAMA 2018 - NDA Filing Planned in 2019 PALO ALTO, Calif. , Dec. 19, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases,
View HTML
Toggle Summary Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 18, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European Medicines
View HTML
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 17, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports on 2018 R&D Day
-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing -- >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif. , Dec. 11, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and
View HTML
Toggle Summary Eiger BioPharmaceuticals to Host R&D Day in New York City
PALO ALTO, Calif. , Dec. 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at the
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company's Chief Financial Officer.  Mr.
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
- Plans to File NDA in 2019 PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S.
View HTML
Toggle Summary Eiger to Participate in Piper Jaffray Healthcare Conference
PALO ALTO, Calif. , Nov. 19, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory , President and CEO, will present a corporate update at the 30 th Annual Piper
View HTML
Toggle Summary Eiger Bio Reports Third Quarter 2018 Financial Results
- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif. , Nov. 9, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of
View HTML
Toggle Summary Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.
View HTML
Toggle Summary Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
PALO ALTO, Calif. , Oct. 18, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
- Lambda Antiviral Activity Demonstrated in HDV Infection - Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif. , Oct. 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary lymphedema of the lower limb demonstrated
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
- Primary and Secondary Endpoints Achieved with Statistical Significance - Avexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences
PALO ALTO, Calif. , Sept. 25, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present at two investor conferences in
View HTML
Toggle Summary Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt of written
View HTML
Toggle Summary Eiger Announces Positive Meeting with FDA on Progeria Program
- Company advancing plans to file NDA for Lonafarnib in Progeria PALO ALTO, Calif. , Sept. 4, 2018 /PRNewswire/ -- Today,  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences
PALO ALTO, Calif. , Aug. 27, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif. , Aug. 13, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  PREVENT is a multi-center, placebo-controlled
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
PALO ALTO, Calif. , Aug. 10, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
PALO ALTO, Calif. , Aug. 7, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO, will present a corporate update at the 2018 Wedbush PacGrow
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study conducted within the National Institutes of
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection
PALO ALTO, Calif. , July 31, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance from the United States Patent and Trademark Office
View HTML
Toggle Summary Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
PALO ALTO, Calif. , June 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
PALO ALTO, Calif. , May 30, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory , President and CEO, will present a corporate update at Jefferies 2018 Global
View HTML
Toggle Summary Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
PALO ALTO, Calif. , May 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , May 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering
View HTML
Toggle Summary Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
- Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif. , May 16, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases,
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
- Hepatitis Delta Virus (HDV) Program Moving into Phase 3 - Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 - Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , May 11, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
PALO ALTO, Calif. , April 17, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented at The International Liver Congress™ 2018, in
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif. , April 2, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in
View HTML
Toggle Summary Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif. , March 26, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif. , March 21, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from a
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018 - Phase 2 Clinical Results Planned from Three Pipeline Programs in 2018 - Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , March 12, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
PALO ALTO, Calif. , March 6, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
PALO ALTO, Calif. , March 5, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at The International Liver Congress™ meeting in Paris, France ,
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
PALO ALTO, Calif. , Feb. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
- End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif. , Jan. 16, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
PALO ALTO, Calif. , Jan. 8, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr.
View HTML
Toggle Summary Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
- ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif. , Jan. 4, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study. 
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif. , Jan. 3, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian , MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
PALO ALTO, Calif. , Jan. 2, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO, will present a corporate update at Biotech Showcase ™
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
PALO ALTO, Calif. , Nov. 13, 2017 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate update at Jefferies
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
-Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 -Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , Nov. 9, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
PALO ALTO, Calif. , Nov. 6, 2017 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will participate and present in three upcoming
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter's Option to Purchase Additional Shares
PALO ALTO, Calif. , Oct. 31, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the closing of its underwritten public offering of
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , Oct. 26, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market
View HTML
Toggle Summary Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif. , Oct. 23, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the Phase 2 LIMT HDV ( L ambda I nterferon M ono T herapy in H epatitis D elta V irus) Study presented at the
View HTML
Toggle Summary Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC , October 20 to 24, 2017 .
View HTML
Toggle Summary Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
- Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif. , Sept. 18, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh , MD to its
View HTML
Toggle Summary Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif. , Sept. 5, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan designation for pegylated
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences
PALO ALTO, Calif. , Aug. 30, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
- Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , Aug. 14, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th
PALO ALTO, Calif. , Aug. 8, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif. , July 27, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for
View HTML
Toggle Summary Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif. , July 24, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment of the Phase 2
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
PALO ALTO , Calif. and SAN DIEGO , June 29, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc. , a private biotechnology company, a non-strategic asset, Mydicar ® (rAAV1-SERCA2a).
View HTML
Toggle Summary Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
- Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif. , June 14, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian , MD, PhD, MBA to
View HTML
Toggle Summary Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
- Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif. , June 12, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced positive data from the Phase 2
View HTML
Toggle Summary Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
PALO ALTO, Calif. , June 6, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending dose (MAD) study evaluating subcutaneous (SC)
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
PALO ALTO, Calif. , May 30, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
- Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif. , May 17, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in
View HTML
Toggle Summary Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
- Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif. , May 15, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 LIBERTY
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
- Five Phase 2 Programs in Four Orphan Indications Progressing - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , May 12, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for
View HTML
Toggle Summary Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
PALO ALTO, Calif. , May 8, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in Chicago , Illinois.  Results from two
View HTML
Toggle Summary Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
- Phase 2 LIBERTY Study Update for Ubenimex in PAH PALO ALTO, Calif. , May 4, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, will host a key opinion leader lunch to address the need for
View HTML
Toggle Summary Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling PALO ALTO, Calif. , May 3, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the U.S.
View HTML
Toggle Summary Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
PALO ALTO, Calif. , April 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois , May 6 to 9, 2017 .
View HTML
Toggle Summary Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
PALO ALTO, Calif. , April 21, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented at The International Liver
View HTML
Toggle Summary Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
- Novel Liquid Formulation of Exendin 9-39 Advancing PALO ALTO, Calif. , April 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the appointment of Lisa Porter , M.D.
View HTML
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif. , April 6, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at the European Association for the Study of the Liver (EASL)
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
- Five Phase 2 Programs in Four Orphan Indications - Multiple Value-Creating Events Across Programs Expected in Next 12-18 Months PALO ALTO, Calif. , March 23, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
PALO ALTO, Calif. , Jan. 30, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger Completes $25 Million Debt Financing with Oxford Finance
PALO ALTO, Calif. , Jan. 4, 2017 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC ("Oxford"), a
View HTML
Toggle Summary Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif. , Jan. 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that the first patient has completed
View HTML
Toggle Summary Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
-- Positive Interim Data from Phase 2 Multiple-Ascending Dose Study -- Novel Liquid Formulation of Exendin 9-39 -- US Orphan Designation for Hyperinsulinemic Hypoglycemia PALO ALTO, Calif. , Dec. 12, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)
- Exendin 9-39 investigational new drug (IND) application filed - PBH Analyst / Key Opinion Leader Event planned December 9th - Multiple-ascending dose (MAD) study interim data to be presented PALO ALTO, Calif. , Nov. 29, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016
PALO ALTO, Calif. , Nov. 21, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical stage biopharmaceuticals company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will
View HTML
Toggle Summary Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
- Update on Data Presented and Analyst Meeting through Monday Evening PALO ALTO, Calif. , Nov. 14, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced presentation of additional data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus)
View HTML
Toggle Summary Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
- Data Presented through Monday Morning PALO ALTO, Calif. , Nov. 14, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced an update on presentations of data from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented as of today at
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
- Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 - Eiger Hosted LOWR HDV Program Key Opinion Leader Review at AASLD 2016 - Four Product Candidates in Four Orphan Indications Continuing to Advance PALO ALTO, Calif.
View HTML
Toggle Summary Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection
- Collaboration with ARUP Laboratories and Hepatitis B Foundation - HDV viral load assay now available in U.S. PALO ALTO, Calif. , Oct. 24, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization
View HTML
Toggle Summary Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif. , Oct. 19, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient was dosed in the
View HTML
Toggle Summary Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
PALO ALTO, Calif. , Oct. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to exendin 9-39 for the treatment
View HTML
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., October 13, 2016 — Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in
View HTML
Toggle Summary Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
PALO ALTO, Calif. , Sept. 7, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the completion of dosing of LOWR HDV – 4 ( LO
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
PALO ALTO, Calif. , Sept. 6, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016
PALO ALTO, Calif. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco . Eiger BioPharmaceuticals management is scheduled to present on
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif. , Aug. 18, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , Aug. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results
- Four Product Candidates in Four Orphan Indications Advancing Toward Near-Term Milestones PALO ALTO, Calif. , Aug. 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare Conference on August 17th
PALO ALTO, Calif. , Aug. 8, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema
Novel first-in-class inhibitor of LTB(4) production targeting disease modification PALO ALTO, Calif. , July 25, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
Novel first-in-class inhibitor of LTB(4) targeting disease modification PALO ALTO, Calif. , July 18, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th
PALO ALTO, Calif., July 6, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the Cantor Fitzgerald 2 nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 9:00 am ET at Le
View HTML
Toggle Summary Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
Oral Presentation at American Diabetes Association Meeting in New Orleans, LA PALO ALTO, Calif. , June 13, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the presentation of positive
View HTML
Toggle Summary Eiger BioPharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
PALO ALTO, Calif. , May 16, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months ended March 31, 2016.     Recent
View HTML
Toggle Summary Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
Novel first-in-class GLP-1 antagonist targeted for rare hypoglycemic condition PALO ALTO, Calif. , May 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first
View HTML
Toggle Summary Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations
PALO ALTO, Calif. , May 3, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan diseases, announced today the appointment of Debra Odink, PhD as the Company's Senior Vice
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb
Including Rights for All Indications and Associated Patents PALO ALTO, Calif. , April 20, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a ("Lambda"), a novel, well-characterized, first in class Type III
View HTML
Toggle Summary Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage
PALO ALTO, Calif. , April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc , (NASDAQ:  EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board. Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing,
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting
PALO ALTO, Calif. , March 30, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) today announced that abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain ,
View HTML
Toggle Summary Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
PALO ALTO, Calif., March 28, 2016 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH).
View HTML
Toggle Summary Eiger BioPharmaceuticals Closes Merger With Celladon
Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PALO ALTO, Calif. , March 22, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. ( NASD : EIGR) today announced completion of its merger with Celladon Corporation
View HTML